AstraZeneca partners with Oxford Biomedica to expand COVID-19 vaccine manufacturing capacity

AstraZeneca has partnered with British cell therapy company Oxford Biomedica to make its experimental COVID-19 vaccine, as the drugmaker looks to bolster its manufacturing capacity to produce one billion doses.